Clinical trials: Pancreas Neoplasm
Genetic Testing, Breast Cancer
Video Education With Result Dependent dIsclosure
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic…
- Conditions
- Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- VERDI (NCT05225428)
- Testing
- Video Education, Genetic Counseling
- Where
- United States
- Volunteers
- 1,334 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreas Cancer
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
Researchers want to discover if the new drug "TG01" will work with participants' bodies to help their immune system attack any cancer cells that might still be in the blood stream after surgery for pancreatic cancer.
- Trial name
- TESLA (NCT05638698)
- Testing
- TG01 Vaccine, QS-21, Balstilimab
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center
Pancreatic Cancer
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00365144
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Cancer
Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma
Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and…
- Trial name
- SINAI (NCT05363007)
- Testing
- nanoliposomal irinotecan, spleen irradiation
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Pancreas Cancer
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer.
- Trial name
- NCT03277209
- Testing
- Plerixafor
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Divestment for Artery-involved Pancreatic Cancer
Pancreatic cancer is the most lethal malignancy of human being. Surgery is the only potential cure of pancreatic cancer. The invasion of major abdominal arteries is one of the most important factor restricting surgical…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Neoadjuvant Therapy, Borderline Resectable Pancreatic Cancer
- Trial name
- NCT03443921
- Testing
- Artery Divestment Technique, Nab-paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Pancreas Pseudocyst
EUS Guided Drainage of Post Pancreatitis Pancreatic Fluid Collection
The number as well as the caliber of plastic stents used for EUS-guided PFC drainage are controversial in current practice [Lin et al., 2014]. The timing of necrosectomy in WOPN drainage continues to be debated.
- Trial name
- NCT06280248
- Testing
- Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst
- Volunteers
- 45 people
- Sponsor
- Assiut University
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer
Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of Sorafenib in combination with Gemcitabine and Radiotherapy Phase II: Activity profile evaluating Progression-free rates (PFR) at 6…
- Trial name
- NCT00789763
- Testing
- Gemcitabine, Radiotherapy, Sorafenib
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Pancreatic Cancer Metastatic
Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?
The recurrent pancreatic cancer (Rec-PC) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer.
- Trial name
- NCT06921252
- Testing
- chemotherapy agents
- Volunteers
- 276 people
- Sponsor
- Kochi University
PDAC - Pancreatic Ductal Adenocarcinoma
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
- Trial name
- CASPER (NCT05853198)
- Testing
- ctDNA analysis
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Pancreatic Cancer
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants.
- Trial name
- NCT00320749
- Testing
- Capecitabine, Docetaxel, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tony Bekaii-Saab
Metastatic Pancreatic Cancer
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer.
- Trial name
- PGPC1 (NCT01461915)
- Testing
- Nab paclitaxel, Gemcitabine, Dociparstat
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Pancreatic Adenocarcinoma
FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX
Pancreatic adenocarcinoma (PAC) incidence increases regularly in Western countries and it is expected to become the second leading cause of cancer-related mortality in 2020.
- Trial name
- GEMFOX (NCT04167007)
- Testing
- Gemcitabine, FOLFOX
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Pancreatic Ductal Adenocarcinoma
Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma
This study introduces a novel transfer learning-based contrastive language-image pretraining adapter (CLIP-adapter) model for predicting the tumor-stroma ratio (TSR) in pancreatic ductal adenocarcinoma (PDAC) using preoperative…
- Trial name
- NCT06302881
- Volunteers
- 207 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.